Linton is one of the world’s leading cannabis executives and an accomplished entrepreneur, with extensive sector experience as a founder, CEO, board member and adviser to a number of global cannabis companies.
He founded Canopy Growth and turned it into the first cannabis producing company listed on the New York Stock Exchange, with a peak market capitalisation of US$15 billion during his six-year tenure.
Deep network of industry contacts
CPH chief executive officer Miri Halperin Wernli said: “Bruce brings a wealth of invaluable knowledge and a deep network of cannabis industry contacts to Creso Pharma and we anticipate that his appointment will greatly assist us in achieving our near term operational milestones and longer-term goals.
“We continue to target international distribution agreements in a number of new markets and progress product development initiatives that will unlock considerable shareholder value. We look forward to providing further updates in the near-term.”
As strategic advisor, Linton will leverage his connections, expertise and influence in the industry to consult and work closely with Creso Pharma’s board to shape the company’s long-term strategy and various near-term corporate and operational initiatives.
Linton believes Creso Pharma is in an optimal position to excel internationally and continue to develop innovative products to complement its existing portfolio.
He says he was attracted to Creso Pharma by its unique IP, established global distribution footprint and robust product pipeline targeting distinct categories.
First cannabis producing company on NYSE
The new strategic advisor has extensive experience in the sector.
At Canopy Growth, he secured 16 rounds of financing of more than US$5 billion in public capital markets and private placements and was involved in more than 30 merger and acquisitions.
After leaving Canopy Growth in 2019, Linton led direct investments into the sector and has held both management positions and strategic advisory roles.
Linton is also the co-founder of Ruckify Software.
He has also worked extensively with international institutions such as the World Bank and has diversified into the psychedelic drug space as director of psychedelic-inspired medicine company Mind Medicine Inc.